Abstract:Abstract Introduction: Despite the numerous drugs available for patients with metastatic colorectal cancer (mCRC), median overall survival for this group of patients remains at ~20-24 months, with no significant advances in the last 7 years. In the US ~50,000 patients die each year from mCRC refractory to systemic therapy. Inhibiting angiogenesis as a therapy has led to a great deal of enthusiasm. However, the overall benefit of classical-antiangiogenic therapy remains modest and has not lived up to their expectations in treating CRC. Our recent studies suggest that VEGF intracrine signaling, rather than autocrine/paracrine signaling, regulates cell survival in CRC cells. Further studies to understand the significance and mechanisms of this novel function have led us to identify factors that intracellularly interact with VEGF. Our studies further indicate that one such interacting protein, SPECC1L, may have a significant role in CRC cell proliferation and may be a potential target in mCRC therapy. Methods: Lysates from CRC cells expressing Myc-tagged VEGF protein were immunoprecipitated and analyzed by mass spectrometry to identify VEGF-interacting protiens. SPECC1L was identified as a co-precipitated protein with high level of confidence. SPECC1L was depleted using siRNA and effects of such depletion on CRC cell growth and morphology were measured by cell growth assays (MTT), microscopy, FACS and western blot analyses. Localization of the protein and its interaction with microtubules and actin were visualized by immunostaining of FLAG-tagged recombinant SPECC1L protein. Results: SPECC1L was identified as a protein that co-immunoprecipitated with Myc-tagged VEGF in CRC cells using mass spectroscopy. Previous literature suggests a role for SPECC1L in cell division. As a fraction of VEGF overexpressing CRC cells have a large multinucleated phenotype, likely arising due to defects in cell division, it was hypothesized that a VEGF mediated regulation of SPECC1L may lead to such phenotype. Depletion of SPECC1L by siRNAs in multiple CRC cell lines led to strong defects in cell division. The effects of SPECC1L depletion were manifested as accumulation of doublet-cells failing to complete cytokinesis following mitosis and resulted in reduced cell proliferation. Failure to complete cell division also led to the formation of multinucleated cells and enhanced cell death. Conclusions: Inhibition of SPECC1L strongly inhibits CRC cell proliferation and enhances cell death. Thus targeting SPECC1L has the potential for developing therapeutics that reduce viability of CRC cells and improve survival of colorectal cancer patients. *** These studies were supported by the Gillson-Longenbaugh Foundation. Citation Format: Rajat Bhattacharya, Ling Xia, Fan Fan, Rui Wang, Delphine Boulbes, Xiang-Cang Ye, David Hawke, Lee Ellis. Depletion of SPECC1L inhibits colorectal cancer cell proliferation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3474. doi:10.1158/1538-7445.AM2017-3474

Blockade of EIF5A hypusination limits colorectal cancer growth by inhibiting MYC elongation

Abstract 3474: Depletion of SPECC1L Inhibits Colorectal Cancer Cell Proliferation

Inhibition of Eukaryotic Translation Initiation Factor 5A (eIF5A) Hypusination Suppress p53 Translation and Alters the Association of eIF5A to the Ribosomes

Hypusination Maintains Intestinal Homeostasis and Prevents Colitis and Carcinogenesis by Enhancing Aldehyde Detoxification

Abstract 566: Therapeutic targeting of the polyamine pathway and EIF5A1 hypusination in endometrial cancer with DFMO and GC7

Hypusinated EIF5A as a feasible drug target for Advanced Medicinal Therapies in the treatment of pathogenic parasites and therapy-resistant tumors

Analysis of the effect of hypusination in myeloid cells on colitis and colitis-associated cancer

MYC upstream region orchestrates resistance to PI3K inhibitors in cancer cells through FOXO3a-mediated autophagic adaptation

Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1‐EEF1A1 Axis

N6-Methyladenosine Reader YTHDF1 Promotes ARHGEF2 Translation and RhoA Signaling in Colorectal Cancer

SMYD5 is a ribosomal methyltransferase that catalyzes RPL40 lysine methylation to enhance translation output and promote hepatocellular carcinoma

RUVBL1/2 Blockade Targets YTHDF1 Activity to Suppress m6A-Dependent Oncogenic Translation and Colorectal Tumorigenesis

Dual Targeting Oncoproteins MYC and HIF1α Regresses Tumor Growth of Lung Cancer and Lymphoma

Eukaryotic translation initiation factor 5A2 (eIF5A2) regulates chemoresistance in colorectal cancer through epithelial mesenchymal transition

β-catenin represses miR455-3p to stimulate m6A modification of HSF1 mRNA and promote its translation in colorectal cancer

Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma

EIF5A1 promotes epithelial ovarian cancer proliferation and progression.

Abstract 10900: Implication of the Post-Translational Formation of Hypusine in Eif5a in Pulmonary Arterial Hypertension

SMYD5 methylation of rpL40 links ribosomal output to gastric cancer

Ubiquitin specific peptidase 5 regulates colorectal cancer cell growth by stabilizing Tu translation elongation factor.

The Histone Acetyltransferase GCN5 Expression is Elevated and Regulated by C-Myc and E2F1 Transcription Factors in Human Colon Cancer.